medigraphic.com

2008, Número 1

<< Anterior Siguiente >>

Arch Cardiol Mex 2008; 78 (1)


Obstrucción en la vía de salida del ventrículo derecho en la miocardiopatía hipertrófica obstructiva. Informe de un caso y revisión de la literatura

Pérez SP, Lomelí EC, Rosas PM, Lorenzo NJA, Mendoza GC, Méndez OA, Attié F

Idioma: Español
Referencias bibliográficas: 39
Paginas: 87-94
Archivo PDF: 223.08 Kb.


RESUMEN

La miocardiopatía hipertrófica obstructiva (MHO) es un trastorno con un amplio espectro de alteraciones morfológicas funcionales y genéticas. La obstrucción de la vía de salida del ventrículo derecho (VD) es un trastorno insospechado la mayoría de las veces, razón por lo que pasa inadvertida y rara vez referida en la literatura cardiológica. Su presentación clínica puede incluir principalmente síntomas de hipertensión venosa sistémica que acompaña a las manifestaciones propias de la miocardiopatía hipertrófica. Las manifestaciones de aparente hipertrofia ventricular derecha en el electrocardiograma (ECG) probablemente son debidos al enorme vector septal que activa el septum con un gran espesor. La confirmación clínica de la obstrucción de la cámara de salida del VD producida por una gran hipertrofia septal asimétrica se demuestra fácilmente con ecocardiografía bidimensional y Doppler.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kizilbash A, Heinle S, Grayburn P: Spontaneous Variability of left Ventricular Outflow Tract Gradient in Hypertrophic Obstructive Cardiomyopathy. Circulation 1998; 97: 461-466.

  2. Klues HG, Schiffers A, Maron BJ: Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995; 26: 1699-1708.

  3. Poliac L, Barron M, Maron BJ: Hypertrophic Cardiomyopathy. Anesthesiology 2006; 104: 183-92.

  4. Maron BJ: Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287: 1308-1320.

  5. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn MJ, Seidman CE, et al: American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the Euroean Society of Cardiology Committee for Practice Guidelines Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2003; 42: 1687-1713.

  6. Maron BH, Gardin JM, Flack JM, Gidding S, Kurosaki T, Bild D: Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation 1995; 92: 785-789.

  7. Wigle ED, Rakowski H, Kimball BP, Williams WG: Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation 1995; 92: 1680-1692.

  8. Maron BJ, Estes NAM III, Maron MS, Almquist AK, Link MS, Udelson: Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation 2003; 107: 2872-2875.

  9. Maron BJ: Hypertrophic cardiomyopathy. Lancet 1997; 350: 127-33.

  10. Delahaye F, Jegaden O, de Gevigney G, Genoud JL, Perinetti M, Montagna P, et al: Postoperative and long term prognosis of myotomy-myomectomy for obstructive hypertrophic cardiomyopathy: Influence of associated mitral valve replacement. Eur Heart J 1993; 14: 1229-37.

  11. Torino A, Galizio N, Guevara E, Valerio E, Favaloro M, Bustamante M et al: Echocardiographic long term follow up in patients with hypertrophic obstructive cardiomyopathy and DD pacing. J Am Society Echocardiogr 1999; 12: 380.

  12. Gaspar J, Martínez-Ríos MA, Vonderwalde C, Rosas M, Ban-Hayashi E, Eidt-Lidt G, Kuri J: Pericardium-covered stent for septal myocardial ablation in hypertrophic obstructive cardiomyopathy. Cathet Cardiovasc Intervent 1999; 47: 73-79.

  13. Nishimura RA, Trusty JM, Hayes DI, Ilstrup DM, Larson DR, Hayes SN et al: Dual-chamber pacing for patients with hypertrophic cardiomyopathy: a prospective randomized doble-blind, crossover trial. J Am Coll Cardiol 1997; 29: 435-41.

  14. Alday L, Bruno E, Moreyra E: Mid-term results of dual-chamber pacing in children with hypertrophic obstructive cardiomyopathy. Ecocardiography 1998; 15: 289-95.

  15. Fernández A, Casabé J, Coronel R, Galizio N, Torino A, Valero E, Mendiz O, Favaloro R: Alternativas terapéuticas en la Miocardiopatía Hipertrófica. Rev Argent Cardiol 2003; 71: 294-301.

  16. Gietzen F, Leuner C, Obergassel L, Strunk-Mueller C, Kuh H: Role of transcoronary Ablation of septal Hypertrophy in Patients With Hypertrophic Cardiomyopathy, New York Heart Association Functional Class III or IV, and Outflow obstruction Only Under Provocable Conditions. Circulation 2002; 106: 454-459.

  17. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ: Magnitude of left ventricular hypertrophy precits the risk of sudden death in Hypertrophy predicts the risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 1778-1785.

  18. Elliott PM, PolonieckiJ, Dickie S, Sharma S, Monserrat L, Varnava A, et al: Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000; 36: 2212-2218.

  19. Maron BJ, Estes NAM III, Maron MS, Almquist AK, Link MS, Udelson: Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation 2003; 107: 2872-2875.

  20. Maron BJ: Sudden death in young athletes. N Engl J Med 2003; 349: 1064-1075.

  21. Krajcer Z, Leachman RD, Cooley DA, Coronado R: Septal myotomy-myomectomy versus mitral valve replacement in hypertrophic cardiomyopathy. Ten years follow-up in 185 patients. Circulation 1989; 80: 157-64.

  22. Jin J, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin D, et al: Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneuos transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 2001; 38: 1994-2000.

  23. Seidman JG, Seidman CE: The genetic basis for cardiomyopathy: fron mutation identification to mechanistic paradigms. Cell 2001; 104: 557-567.

  24. Maron BJ, Niimura H, Casey SA, Soper MK, Wright GB, Seidman J, et al: Development of left ventricular hypertrophy in adults with hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C mutations. J Am Coll Cardiol. 2001; 38: 315-321.

  25. McIntosh CL, Greenberg GJ, Maron BJ, Leon MB, Cannon RO 3rd, Clark RE, et al: Clinical and hemodynamic results after mitral valve replacement in patients with obstructive hypertrophic cardiomyopathy. Ann Thorac Surg 1989; 47: 236-46.

  26. Bonne G, Carrier L, Richard P, Hainque B, Schwartz K: Familial hypertrophic cardiomyopathy: from mutations to functional defects. Circ Res 1998; 83: 580-593.

  27. Fananapazir L, Epstein ND: Genotype-phenotype correlations in hypertrophic cardiomyopathy: insights provided by comparisons of kindreds with distinct and identical B-myosin heavy chain gene mutations. Circulation 1994; 89: 22-32.

  28. Epstein ND, Cohn GM, Cyran F, Fananapazir L: Differences in clinical expression of hypertrophic cardiomyiopathy associated with two distinct mutations in the B-myosin heavy chain gene: a 908Leu-Val mutation and a 403ArgGln mutation. Circulation 1992; 86: 345-352.

  29. Thierfleder L, Watkins H, MacRae C, Lamas R, McKenna W, Vosberg H, et al: a-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994; 77(5): 701-712.

  30. Maron M, Olivotto I, Senovich A, Link M, Pandian N, Kuvin J, et al: Hypertrophic Cardiomyopath is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction. Circulation 2006; 114: 2232-2239.

  31. Maldonado B, Calderón J, de Micheli A, Casanova J, Rijlaarsdam M, Buendía A, et al: Aspectos electrocardiográficos de la Miocardiopatía Hipertrófica en la edad pediátrica. Arch Inst Cardiol Mex 2000; 70(3): 247-260.

  32. Frank S, Braunwald E: Idiopathic hypertrophic Subaortic stenosis: clinical analysis of 126 patients with emphasis on the natural history. Circulation 1968; 37: 759-788.

  33. Shimizu M, Hawai H, Yolota Y, Yokohama M: Echocardiographic assessment of right ventricular obstruction in Hypertrophic Cardiomyopathy. Circ J 2003; 67: 855-860.

  34. Falcone DM, Moore D, Lambert EC: Idiopatic hypertrophic cardiomyopathy involving the right ventricle. Am J Cardiol 1967; 19: 735-740.

  35. Kampmann C, Baehner FA, Whybra C, Bajbouj M, Baron K, Knuf M, et al: The right ventricule in Fabry disease. Acta Paediatr Suppl 2005; 94(447): 15-8.

  36. Spirito P, Seidman CE, McKenna WJ, Maron BJ: The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336: 775-785.

  37. Sigwart U: Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995; 346: 211-4.

  38. Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, et al: Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001; 38: 1701-6.

  39. Faber L, Seggewiss H, Gleichmann U: Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. Results with respect to intraprocedural myocardial contrast echocardiography. Circulation 1998; 98: 2415-21.




2020     |     www.medigraphic.com